Skip to main content
Premium Trial:

Request an Annual Quote

Melanoma MDx Firm DermTech Withdraws Planned $15M IPO

NEW YORK (GenomeWeb) – Melanoma test development firm DermTech is pulling its proposed initial public offering.

The La Jolla, Calif.-based firm filed a request with the US Securities and Exchange Commission on Thursday saying it seeks an "immediate withdrawal" of its Form S-1 "as it has determined not to proceed with an offering at this time." It did not provide a reason for the withdrawal.

DermTech filed its registration form in May to offer its shares on the Nasdaq Capital Market under ticker symbol "DMTK." The Maxim Group and Feltl & Co., were the underwriters on the offering. It originally planned an offering of up to $25 million of its shares but lowered its target to $15 million in August.

The firm develops gene expression tests for diagnosing skin conditions, including skin cancer, inflammatory diseases, and age-related conditions. Its technology uses an "adhesive patch biopsy" that provides a tissue sample non-invasively, DermTech said in its Form S-1. Skin cells are then analyzed via a qPCR-based method.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.